化疗联合沙利度胺及健脾养阴活血方治疗晚期结直肠癌合并重度营养不良的效果观察  

Effect Observation on Chemotherapy Combined with Thalidomide and Jianpi Yangyin Huoxue Formula in the Treatment of Late Colorectal Cancer Complicated with Severe Inanition

作　　者：王芙 WANG Fu(The General Hospital of Yima Coal Group Co.Ltd.,Yima,Henan 472300)

机构地区：[1]义马煤业集团股份有限公司总医院,河南义马472300

出　　处：《中国肛肠病杂志》2021年第10期8-10,共3页Chinese Journal of Coloproctology

摘　　要：为观察化疗联合沙利度胺及健脾养阴活血方治疗晚期结直肠癌合并重度营养不良患者的效果,将154例晚期结直肠癌合并重度营养不良患者随机分为沙利度胺组和中西联合治疗组,每组77例。沙利度胺组患者在化疗基础上联合沙利度胺治疗,中西联合治疗组患者在化疗基础上联合沙利度胺及健脾养阴活血方治疗,比较2组患者的疗效、不良反应发生情况及治疗后营养状态。结果显示,2组患者治疗有效率无显著性差异(P>0.05);中西联合治疗组胃肠道反应、肝肾功能损伤及骨髓抑制不良反应发生率为22.08%,明显低于沙利度胺组的41.56%(P<0.05);营养支持后2组患者的主观整体评估(PGSGA)评分无显著性差异(P>0.05),治疗8周后中西联合治疗组PG-SGA评分低于沙利度胺组(P<0.05)。结果表明,健脾养阴活血方可明显降低不良反应发生率,改善患者营养状况,有一定的临床应用价值。This study was to observe the effect of chemotherapy combined with thalidomide and Jianpi yangyin huoxue formula(a TCM formula,shortly named as Formula)in the treatment of late colorectal cancer(LCRC)complicated with severe inanition,randomly divided 154patients with above conditions into thalidomide group(77cases,chemotherapy plus thalidomide)and combination group(77cases,chemotherapy+thalidomide,also,Formula);then,compared both groups'effect,unward reaction status,and patients'nutrition situation after treatment.As results,in effective rate there was no statistical difference between the two groups(P>0.05);in the incidence of unward reactions such as gastrointestinal responses,the trauma of liver and kidney function,and bone marrow suppression,combination group was significantly lower than thalidomide group(22.08%vs 41.56%,P<0.05);after nutrition support,both groups'ratings of PG-SGA had no significant difference each other(P>0.05),but after 8weeks of treatment the ratings of combination group were lower than that of thalidomide group(P<0.05).Results show that Formula can significantly reduce unward reaction's incidence,improve patients'nutrition situation,and has clinically certain using value.

关 键 词：结直肠癌 重度营养不良 化疗 沙利度胺 健脾养阴活血方 

分 类 号：R735.34[医药卫生—肿瘤]